{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:06:52Z","timestamp":1773446812542,"version":"3.50.1"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Background: Mucormycosis, an invasive fungal infection with high morbidity and mortality rates, requires prompt surgical and antifungal therapies; however, the role of antifungal susceptibility testing (AFST) in clinical management of mucormycosis remains underexplored. We aimed to describe the experience of using AFST in the clinical management of mucormycosis. Methods: We conducted a retrospective study from 1 October 2017 to 8 February 2023. We included non-pregnant patients aged \u2265 18 years old with a positive culture for Mucorales and with proven or probable mucormycosis. We collected clinical and microbiological data using a chart review. Results: Over the study period, a total of 119 patients were included, with 36 (30%) undergoing AFST. Of all patients, the median age was 54 years, with 80 (67%) being White and not Hispanic and 73 (61%) being male. Fifty-three (45%) patients had DM, 27 (23%) had hematological malignancy, 15 (13%) had SOT, and 23 (19%) had COVID-19. Half of the cases met the criteria of proven invasive mucormycosis, with pulmonary involvement being the most common presentation (46, 39%), followed by rhino-cerebral-orbital involvement (35, 29%). The majority of Mucorales isolates were Rhizopus species (79, 66%). Among the 36 who underwent AFST, posaconazole minimal inhibitory concentrations (MICs) were lower than isavuconazole (range 0.03 to 2 \u00b5g\/mL versus 0.1 to 16 \u00b5g\/mL, respectively). AFST resulted in a change in antifungal therapy from isavuconazole to posaconazole in 3\/36 (8%) cases. There was no statistically significant difference in the mortality between the patients whose isolates received AFST versus those who did not have AFST performed. Conclusions: AFST led to a change in antifungal therapy in a minority of mucormycosis cases. Further studies to understand the epidemiological range of antifungal MICs and the effect of AFST-informed antifungal therapy are needed.<\/jats:p>","DOI":"10.3390\/jof12010034","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T11:11:46Z","timestamp":1767352306000},"page":"34","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifungal Susceptibility Testing Experience in the Management of Culture-Positive Mucormycosis: Observation from a Large Healthcare System"],"prefix":"10.3390","volume":"12","author":[{"given":"Maryam","family":"Naveed","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Arizona College of Medicine, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tirdad T.","family":"Zangeneh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Arizona College of Medicine, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":false,"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9372-6737","authenticated-orcid":false,"given":"William","family":"Lainhart","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Arizona College of Medicine, Tucson, AZ 85724, USA"},{"name":"Department of Pathology and Laboratory Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-6594","authenticated-orcid":false,"given":"Mohanad M.","family":"Al-Obaidi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Arizona College of Medicine, Tucson, AZ 85724, USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0039-3401992","article-title":"Mucormycosis","volume":"41","author":"Reid","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_2","unstructured":"WHO (2022). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action, WHO. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240060241."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.idc.2021.03.009","article-title":"Mucormycosis","volume":"35","author":"Steinbrink","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e0123021","DOI":"10.1128\/JCM.01230-21","article-title":"Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States","volume":"59","author":"Badali","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global Guideline for the Diagnosis and Management of Mucormycosis: An Initiative of the European Confederation of Medical Mycology in Cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.46.7.2310-2312.2002","article-title":"In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole Treatment for Mucormycosis: A Single-Arm Open-Label Trial and Case-Control Analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1128\/AAC.05956-11","article-title":"In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: Poor efficacy of posaconazole","volume":"56","author":"Salas","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","unstructured":"(2022). Performance Standards for Antifungal Susceptibility Testing of Yeasts, 3rd ed. (Standard No. CLSI M27M44S). Available online: https:\/\/clsi.org."},{"key":"ref_11","unstructured":"EUCAST (2024). Clinical Breakpoints for Fungi (Candida and Aspergillus Species), EUCAST. Available online: https:\/\/www.eucast.org\/astoffungi\/clinicalbreakpointsforantifungals."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1473-3099(22)00124-4","article-title":"Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India","volume":"22","author":"Muthu","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3201\/eid2901.220926","article-title":"Multicenter Case-Control Study of COVID-19-Associated Mucormycosis Outbreak, India","volume":"29","author":"Muthu","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","unstructured":"(2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, 3rd ed. (Standard No. CLSI M38Ed3)."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1128\/AAC.01467-08","article-title":"Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers","volume":"53","author":"Castelli","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2147\/IDR.S360191","article-title":"In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China","volume":"15","author":"Jing","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lackner, M., Toepfer, S., Keniya, M.V., Lax, C., Nicolas, F.E., Garre, V., M\u00fcller, C., Rosam, K., Zenz, L.-M., and Cesarini, L. (2025). The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus. Antimicrob. Agents Chemother., e0133725.","DOI":"10.1128\/aac.01337-25"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/1\/34\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T11:41:12Z","timestamp":1767354072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/1\/34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jof12010034"],"URL":"https:\/\/doi.org\/10.3390\/jof12010034","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}